Strong results from GSK’s hepatitis B drug, engineered heart patches, and more biotech news from The Readout
Adobe
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Scientists are reporting early but meaningful progress in engineered heart patches, and GSK has a functional cure for hepatitis B — at least for some of the patient population.
Also, some new drug launches might, or might not, shed light on whether President Trump really can claim the U.S. has “most-favored nation” status. And we discuss what’s most exciting at the upcoming ASCO meeting in Chicago. (We’ve got a pop-up newsletter on the way. Sign up!)
